Zacks Research Issues Optimistic Outlook for ResMed Earnings

ResMed Inc. (NYSE:RMD - Free Report) - Investment analysts at Zacks Research raised their Q1 2026 earnings per share (EPS) estimates for shares of ResMed in a research report issued to clients and investors on Monday, July 14th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $2.40 for the quarter, up from their previous estimate of $2.37. The consensus estimate for ResMed's current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed's Q2 2026 earnings at $2.49 EPS, Q3 2026 earnings at $2.52 EPS, FY2026 earnings at $9.87 EPS, Q1 2027 earnings at $2.53 EPS, Q2 2027 earnings at $2.64 EPS and Q3 2027 earnings at $2.74 EPS.

Other equities research analysts have also issued research reports about the company. KeyCorp set a $274.00 price objective on ResMed in a research note on Thursday, April 24th. JPMorgan Chase & Co. lifted their target price on ResMed from $286.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, April 24th. Mizuho lifted their target price on ResMed from $250.00 to $270.00 and gave the stock an "outperform" rating in a research report on Wednesday. Piper Sandler decreased their target price on ResMed from $260.00 to $248.00 and set a "neutral" rating for the company in a research report on Thursday, April 24th. Finally, Morgan Stanley set a $286.00 target price on ResMed and gave the stock an "overweight" rating in a research report on Tuesday, May 20th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, ResMed has a consensus rating of "Moderate Buy" and an average price target of $263.00.

ResMed Stock Up 0.5%

NYSE RMD traded up $1.17 during mid-day trading on Wednesday, reaching $257.59. 288,046 shares of the company's stock traded hands, compared to its average volume of 965,943. ResMed has a 1-year low of $196.43 and a 1-year high of $263.05. The company has a fifty day simple moving average of $251.28 and a 200-day simple moving average of $237.32. The company has a current ratio of 3.41, a quick ratio of 2.49 and a debt-to-equity ratio of 0.12. The company has a market cap of $37.77 billion, a price-to-earnings ratio of 28.94, a P/E/G ratio of 1.59 and a beta of 0.77.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share for the quarter, beating analysts' consensus estimates of $2.36 by $0.01. ResMed had a return on equity of 25.67% and a net margin of 26.15%. The firm had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.28 billion. During the same quarter last year, the firm earned $2.13 EPS. ResMed's quarterly revenue was up 7.9% on a year-over-year basis.

ResMed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 12th. Shareholders of record on Thursday, May 8th were paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 0.82%. The ex-dividend date was Thursday, May 8th. ResMed's payout ratio is currently 23.79%.

Insider Buying and Selling at ResMed

In other ResMed news, Director Witte Jan De sold 2,000 shares of ResMed stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $243.47, for a total transaction of $486,940.00. Following the sale, the director owned 5,806 shares of the company's stock, valued at $1,413,586.82. The trade was a 25.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Peter C. Farrell sold 945 shares of the business's stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $255.49, for a total value of $241,438.05. Following the completion of the sale, the director directly owned 68,273 shares in the company, valued at $17,443,068.77. This represents a 1.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,013 shares of company stock valued at $7,238,913 in the last quarter. Corporate insiders own 0.71% of the company's stock.

Institutional Trading of ResMed

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Pacific Point Advisors LLC raised its stake in shares of ResMed by 5.8% in the 2nd quarter. Pacific Point Advisors LLC now owns 6,220 shares of the medical equipment provider's stock worth $1,605,000 after buying an additional 341 shares in the last quarter. Institute for Wealth Management LLC. bought a new stake in shares of ResMed in the 2nd quarter worth $260,000. Truist Financial Corp raised its stake in shares of ResMed by 1.7% in the 2nd quarter. Truist Financial Corp now owns 10,660 shares of the medical equipment provider's stock worth $2,750,000 after buying an additional 183 shares in the last quarter. Archford Capital Strategies LLC bought a new stake in shares of ResMed in the 2nd quarter worth $326,000. Finally, FARMERS & MERCHANTS TRUST Co OF LONG BEACH acquired a new stake in shares of ResMed during the second quarter worth $215,000. Institutional investors own 54.98% of the company's stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.